Related Experiment Videos
[Meningococcosis in Tunisia. Apropos of 80 cases]
H Pousse1, R Ben Mbarek, A Ayachi
1Service de Pédiatrie, Hôpital Tahar-Sfar de Mahdia, Tunisie.
Abstract:
Meningococcosis are nowadays an health problem because their incidence rate (38 cases/100,000 people in 1986 in Mahdia region) and a high death rate (40%) due to fulminating forms. At the occasion of a prospective study during the first six months of 1987, the authors report the emergence of C serogroup (21%), the smallness of A serogroup (6.50%) and the predominance of B serogroup (68%). Improving level of living, good prophylaxy based on spiramycin, development of use of meningococcal vaccine are advisable means to control epidemic outbreaks.
Insights
Meningococcosis poses a significant health risk due to high incidence and mortality. Serogroup B predominated in a 1987 study, highlighting the need for vaccination and improved public health measures.
Area of Science:
- Epidemiology
- Public Health
- Infectious Diseases
Background:
- Meningococcosis presents a considerable public health challenge, characterized by a high incidence rate (38 cases/100,000 in 1986) and a significant mortality rate (40%) attributed to fulminating forms.
- The Mahdia region experienced a notable burden of meningococcal disease in 1986.
Purpose of the Study:
- To prospectively investigate the serogroup distribution of Neisseria meningitidis during the first six months of 1987.
- To inform public health strategies for controlling meningococcal disease outbreaks.
Main Methods:
- A prospective study was conducted over a six-month period in 1987.
- Serogroup identification of meningococcal isolates was performed.
Main Results:
- The study identified a predominance of Serogroup B (68%) among meningococcal isolates.
- Serogroup C emerged as a significant factor (21%), while Serogroup A was less prevalent (6.50%).
Conclusions:
- The findings underscore the importance of serogroup surveillance for effective meningococcal disease control.
- Recommendations include improving living standards, implementing prophylaxis with spiramycin, and promoting meningococcal vaccine use to mitigate epidemic potential.